Evidence map›Paper›PMID 38179031›Full record

ArticleBJUI compass2024

Patient experiences with tissue-based genomic testing during active surveillance for prostate cancer.

Michael S Leapman, Ryan Sutherland, Cary P Gross, Xiaomei Ma, Tyler M Seibert, Matthew R Cooperberg, William J Catalona, Stacy Loeb, Dena Schulman-Green

Open access · goldAbstract read
In one paragraph

Article in BJUI compass, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 6 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 7 institutions in 1 country.

Michael S LeapmanDepartment of Urology Yale School of Medicine New Haven Connecticut USA.ORCID https://orcid.org/0000-0002-0727-7614
Ryan SutherlandYale School of Medicine New Haven Connecticut USA.
Cary P GrossYale Cancer Outcomes Public Policy, and Effectiveness Research Center New Haven Connecticut USA.
Xiaomei MaYale Cancer Outcomes Public Policy, and Effectiveness Research Center New Haven Connecticut USA.
Tyler M SeibertDepartment of Radiation Medicine and Applied Sciences University of California San Diego La Jolla California USA.
Matthew R CooperbergDepartment of Urology University of California San Francisco San Francisco California USA.ORCID https://orcid.org/0000-0003-4339-6685
William J CatalonaDepartment of Urology Northwestern University Feinberg School of Medicine Chicago Illinois USA.
Stacy LoebDepartments of Urology and Population Health New York University Langone Health New York New York USA.
Dena Schulman-GreenNew York University Rory Meyers College of Nursing New York New York USA.
Yale Cancer Center · USNew York University · USNorthwestern University · USUniversity of California San Diego · USUniversity of California, San Francisco · USVeterans Health Administration · USYale University · US

Funding

Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9M
Targeting FOXA1-downstream pathways: a novel therapeutic strategy for castration-resistant prostate cancerP50CA180995 · NCI · NORTHWESTERN UNIVERSITY AT CHICAGO · PI ABDULKADIR, SARKI A. · 2015 to 2025
$19.9M
Mechanistic Dissection of an Arginine Methyltransferase Dependency in CancerK08CA204732 · NCI · YALE UNIVERSITY · PI WILSON, FREDERICK H · 2017 to 2021
$876k
NCATS NIH HHS UL1 TR001863NCI NIH HHS K08 CA204732NCI NIH HHS P50 CA180995
6 · The paper itself

Abstract

Background: Tissue-based gene expression (genomic) tests provide estimates of prostate cancer aggressiveness and are increasingly used for patients considering or engaged in active surveillance. However, little is known about patient experiences with genomic testing and its role in their decision-making. Methods: We performed a qualitative study consisting of in-depth, semi-structured interviews of patients with low- or favourable-intermediate-risk prostate cancer managed with active surveillance. We purposively sampled to include patients who received biopsy-based genomic testing as part of clinical care. The interview guide focused on experiences with genomic testing during patients' decision-making for prostate cancer management and understanding of genomic test results. We continued interviews until thematic saturation was reached, iteratively created a code key and used conventional content analysis to analyse data. Results: Participants' ( Conclusion: Patients interact with and are influenced by the results of biopsy-based genomic testing during active surveillance for prostate cancer, despite gaps in understanding about test results. Our findings indicate areas for improvement in patient counselling in order to increase patient knowledge and comfort with genomic testing.

Indexed as

active surveillancebiomarkersdecision‐makinggenomic testingprostate cancerqualitative

Identifiers

PMID38179031
PMCPMC10764160
OpenAlexW4386000674

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.